NASDAQ:SHPH Shuttle Pharmaceuticals Q1 2025 Earnings Report $5.56 +0.85 (+18.11%) As of 12:10 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Shuttle Pharmaceuticals EPS ResultsActual EPS-$75.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AShuttle Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AShuttle Pharmaceuticals Announcement DetailsQuarterQ1 2025Date5/8/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Shuttle Pharmaceuticals Earnings HeadlinesShuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026September 24, 2026 | marketscreener.comMShuttle Pharmaceuticals Restructures Capital Through New SecuritiesSeptember 16, 2026 | tipranks.comWhy The Biggest Names in AI Are Heading To The ArcticGoogle contracted over 12 GW of energy last year and just announced a 15 billion dollar AI infrastructure investment in Finland. Cerebras followed with plans for a 165 MW data center worth up to 1.7 billion euros. One small Nasdaq-listed company built its Nordic footprint before this wave hit, with up to 190 MW of capacity approaching ready-for-service status in 2027 to early 2028. Recent long-term data center deals have valued capacity at 1.7 to 2 million dollars per MW annually. See why this overlooked company could be next in the AI infrastructure spotlight.October 8 at 1:00 AM | The Tomorrow Investor (Ad)Shuttle Pharmaceuticals Shareholders Approve Merger and RenamingSeptember 11, 2026 | tipranks.comShuttle Pharmaceuticals Reschedules Upcoming Special Stockholder MeetingSeptember 2, 2026 | tipranks.comShuttle Pharmaceuticals Revises Merger Milestones, Affecting Capital StructureSeptember 1, 2026 | tipranks.comSee More Shuttle Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Shuttle Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shuttle Pharmaceuticals and other key companies, straight to your email. Email Address About Shuttle PharmaceuticalsShuttle Pharmaceuticals (NASDAQ:SHPH) is a clinical-stage specialty pharmaceutical company focused on developing therapies designed to improve the effectiveness of radiation treatment for cancer patients. The company’s research centers on radiosensitizers, which are intended to make tumor cells more sensitive to radiation while helping preserve surrounding healthy tissue. Shuttle’s lead product candidate is ropidoxuridine, an orally administered investigational therapy being developed for use in combination with radiation therapy. The company has also pursued additional drug candidates and formulations intended to address unmet needs in oncology and improve treatment outcomes for patients undergoing radiotherapy. Based in Rockville, Maryland, Shuttle Pharmaceuticals conducts its development activities in the United States. Its programs remain investigational and are subject to clinical testing and regulatory review before any product can be marketed.View Shuttle Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand ExplodesDoes Lemonade’s Growth Signal Profits Ahead?Wall Street Is Betting These 3 Beaten-Down Stocks Have More Room to Run Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
